Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Voriconazole

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 3 (1)

Trial Status

Not Yet Recruiting2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06729216Not Yet RecruitingPrimary

Fungal Resistance in Dermatophyte Infection

NCT06680544Phase 2Not Yet RecruitingPrimary

Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections

NCT04880980Phase 3CompletedPrimary

Comparison of Efficacy of Double Dose Oral Terbinafine Vs Itraconazole in Treatment of Dermatophyte Infections of Skin.

Showing all 3 trials

Research Network

Common Treatments

  • Voriconazole1
  • Antifungal Susceptibility Testing Afst1
  • Itraconazole1
  • Terbinafine1

Active Sponsors

  • Sheikh Zayed Medical College1
  • Cairo University1
  • Pak Emirates Military Hospital1

Top Investigators

Related Conditions

  • Itraconazole Adverse Reaction1
  • Terbinafine Adverse Reaction1

Activity Timeline